Skip to Content
MilliporeSigma
  • Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial.

Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial.

JAMA dermatology (2014-06-13)
Murad Alam, Sandra Han, Marisa Pongprutthipan, Wareeporn Disphanurat, Rohit Kakar, Michael Nodzenski, Natalie Pace, Natalie Kim, Simon Yoo, Emir Veledar, Emily Poon, Dennis P West
ABSTRACT

Neocollagenesis can be achieved using a dermal rolling needle device, thereby reducing the appearance of acne scars. To determine the efficacy of a needling device for treatment of acne scars. We performed a single-center, rater-blinded, balanced (1:1), split-face, placebo-controlled, parallel-group randomized clinical trial at an urban academic institution. The study took place from November 30, 2009, through July 27, 2010. Twenty healthy adults (age range, 20-65 years) with acne scars on both sides of the face were enrolled. Fifteen individuals completed the study, and no enrolled participants were withdrawn for adverse effects. For each participant, one side of the face was randomized for needling. Three needling treatments were performed at 2-week intervals. Two blinded dermatologists separately rated participants' acne scars based on standard digital photographs obtained at baseline and at the 3-month and 6-month follow-up visits on the quantitative global scarring grading system. Mean scar scores were significantly lower in the treatment group compared with baseline at 6 months (mean difference, 3.4; 95% CI, 0.2-6.5; P = .03) and nominally but not significantly lower compared with baseline at 3 months (mean difference, 2.4; 95% CI, -0.01 to 4.8; P = .052). In the control group, mean scar scores did not vary significantly from baseline at 3 months (mean difference, 1.0; 95% CI, -1.4 to 3.4; P = .96) and at 6 months (mean difference, 0.4; 95% CI, -2.3 to 3.5; P > .99). The needling procedure was not particularly painful, with a mean pain rating of 1.08 of 10. Participants perceived a 41% mean improvement in overall scar appearance on the treated side. No adverse events were reported. After 3 needling treatments, there was improvement in the appearance of acne scars over time compared with the control group, with minimal pain reported. clinicaltrials.gov Identifier: NCT00974870.

MATERIALS
Product Number
Brand
Product Description

Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Lidocaine, European Pharmacopoeia (EP) Reference Standard
Prilocaine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Lidocaine, analytical standard
Sigma-Aldrich
Lidocaine, powder
USP
Lidocaine, United States Pharmacopeia (USP) Reference Standard